10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.
Joseph A. Sparano
No relevant relationships to disclose
Anne O'Neill
No relevant relationships to disclose
Robert James Gray
Research Funding - Genomic Health
Edith A. Perez
No relevant relationships to disclose
Lawrence N. Shulman
No relevant relationships to disclose
Silvana Martino
No relevant relationships to disclose
Sunil S. Badve
Honoraria - Genomic Health
Frederick L. Baehner
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Barrett H Childs
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Carl N. Yoshizawa
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Steve Rowley
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Nancy E. Davidson
No relevant relationships to disclose
Steven Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Lori J. Goldstein
Consultant or Advisory Role - Genomic Health (U)